Top

Endocrine

Published in:

01-07-2017 | Original Article

The relationship of 19 functional polymorphisms in iodothyronine deiodinase and psychological well-being in hypothyroid patients

Authors: Yoon Young Cho, Hye Jeong Kim, Hye Won Jang, Tae Hyuk Kim, Chang-Seok Ki, Sun Wook Kim, Jae Hoon Chung

Published in: Endocrine | Issue 1/2017

Abstract

Purpose

Levothyroxine supplementation is insufficient for the management of one tenth of patients with hypothyroidism. Iodothyronine deiodinases have been suggested to play a role in residual hypothyroid symptoms of these patients by controlling local thyroid hormone homeostasis. Previous research has suggested a relationship between commonly inherited variations in type 2 iodothyronine deiodinase and impaired well-being. We evaluated the prevalence of iodothyronine deiodinase genotypes and their association with psychological well-being in the Korean hypothyroid population.

Methods

A prospective observational study. We enrolled 196 hypothyroid subjects (136 chronic autoimmune thyroiditis and 60 thyroid cancer) and assessed baseline well-being using six validated questionnaires. Genotyping was conducted for 19 single nucleotide polymorphisms in type 1, 2, and 3 iodothyronine deiodinase using Sequenom MassARRAY matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in all patients.

Results

Frequencies of iodothyronine deiodinase genotypes and well-being scores were not different in hypothyroid subjects according to their disease types. Minor genotypes of a few iodothyronine deiodinase 1 variants (rs11206244, rs2294512, and rs4926616) were associated with reduced psychological well-being. However, iodothyronine deiodinase 2 and 3 variants had no effect on baseline well-being.

Conclusion

Minor variations in iodothyronine deiodinase 1 were associated with decreased well-being in the Korean hypothyroid population, whereas iodothyronine deiodinase 2 and 3 were not. Due to controversial results among different ethnicities, further studies to clarify the effects of iodothyronine deiodinase polymorphisms on psychological well-being are warranted in hypothyroid individuals.

M.P. Vanderpump, The epidemiology of thyroid disease. Br. Med. Bull. 99, 39–51 (2011). doi:10.1093/bmb/ldr030 CrossRefPubMed

G.H. Seo, J.H. Chung, Incidence and prevalence of overt hypothyroidism and causative diseases in Korea as determined using claims data provided by the health insurance review and assessment service. Endocrinol. Metab. 30, 288–296 (2015). doi:10.3803/EnM.2015.30.3.288 CrossRef

J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 24, 1670–1751 (2014). doi:10.1089/thy.2014.0028 CrossRefPubMedPubMedCentral

W.M. Wiersinga, L. Duntas, V. Fadeyev, B. Nygaard, M.P. Vanderpump, 2012 ETA guidelines: the use of L-T4+L-T3 in the treatment of hypothyroidism. Eur. Thyroid. J. 1, 55–71 (2012). doi:10.1159/000339444 CrossRefPubMedPubMedCentral

G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway, The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000)CrossRef

B. Gereben, E.A. McAninch, M.O. Ribeiro, A.C. Bianco, Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat. Rev. Endocrinol. 11, 642–652 (2015). doi:10.1038/nrendo.2015.155 CrossRefPubMedPubMedCentral

L.E. Braverman, S.H. Ingbar, K. Sterling, Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J. Clin. Invest. 49, 855–864 (1970). doi:10.1172/jci106304 CrossRefPubMedPubMedCentral

R. Bunevicius, G. Kazanavicius, R. Zalinkevicius, A.J. Prange Jr., Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N. Engl. J. Med. 340, 424–429 (1999). doi:10.1056/nejm199902113400603 CrossRefPubMed

B. Nygaard, E.W. Jensen, J. Kvetny, A. Jarlov, J. Faber, Effect of combination therapy with thyroxine (T4) and 3,5,3’-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur. J. Endocrinol. 161, 895–902 (2009). doi:10.1530/eje-09-0542 CrossRefPubMed

10.

P. Saravanan, D.J. Simmons, R. Greenwood, T.J. Peters, C.M. Dayan, Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. J. Clin. Endocrinol. Metab. 90, 805–812 (2005). doi:10.1210/jc.2004-1672 CrossRefPubMed

11.

M. Valizadeh, M.R. Seyyed-Majidi, H. Hajibeigloo, S. Momtazi, N. Musavinasab, M.R. Hayatbakhsh, Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Endocr. Res. 34, 80–89 (2009). doi:10.1080/07435800903156340 CrossRefPubMed

12.

V. Panicker, P. Saravanan, B. Vaidya, J. Evans, A.T. Hattersley, T.M. Frayling, C.M. Dayan, Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J. Clin. Endocrinol. Metab. 94, 1623–1629 (2009). doi:10.1210/jc.2008-1301 CrossRefPubMed

13.

R.A. Philibert, S.R. Beach, T.D. Gunter, A.A. Todorov, G.H. Brody, M. Vijayendran, L. Elliott, N. Hollenbeck, D. Russell, C. Cutrona, The relationship of deiodinase 1 genotype and thyroid function to lifetime history of major depression in three independent populations. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156B, 593–599 (2011). doi:10.1002/ajmg.b.31200 CrossRefPubMed

14.

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26, 1–133 (2016). doi:10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral

15.

H. Jung, C.S. Ki, J.W. Kim, E.S. Kang, Frequencies of 10 autosomal minor histocompatibility antigens in Korean population and estimated disparities in unrelated hematopoietic stem cell transplantation. Tissue. Antigens. 79, 42–49 (2012). doi:10.1111/j.1399-0039.2011.01810.x CrossRefPubMed

16.

J.E. Ware Jr., C.D. Sherbourne, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. 30, 473–483 (1992)CrossRef

17.

Y.S. Rhee, D.O. Shin, K.M. Lee, H.J. Yu, J.W. Kim, S.O. Kim, R. Lee, Y.O. Lee, N.S. Kim, Y.H. Yun, Korean version of the caregiver quality of life index-cancer (CQOLC-K). Qual. Life. Res. 14, 899–904 (2005)CrossRef

18.

J.E. Ware Jr., B. Gandek, M. Kosinski, N.K. Aaronson, G. Apolone, J. Brazier, M. Bullinger, S. Kaasa, A. Leplege, L. Prieto, M. Sullivan, K. Thunedborg, The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J. Clin. Epidemiol. 51, 1167–1170 (1998)CrossRef

19.

A.S. Zigmond, R.P. Snaith, The hospital anxiety and depression scale. Acta. Psychiatr. Scand. 67, 361–370 (1983)CrossRef

20.

S.M. Oh, K.J. Min, D.B. Park, A study on the standardization of the hospital anxiety and depression scale for Koreans: a comparison of normal, depressed and anxious groups. J. Korean Neuropsychiatr. Assoc. 38, 289–296 (1999)

21.

T.R. Mendoza, X.S. Wang, C.S. Cleeland, M. Morrissey, B.A. Johnson, J.K. Wendt, S.L. Huber, The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer. 85, 1186–1196 (1999)CrossRef

22.

Y.H. Yun, X.S. Wang, J.S. Lee, J.W. Roh, C.G. Lee, W.S. Lee, K.S. Lee, S.M. Bang, T.R. Mendoza, C.S. Cleeland, Validation study of the korean version of the brief fatigue inventory. J. Pain. Symptom. Manage. 29, 165–172 (2005). doi:10.1016/j.jpainsymman.2004.04.013 CrossRefPubMed

23.

P. Saravanan, W.F. Chau, N. Roberts, K. Vedhara, R. Greenwood, C.M. Dayan, Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin. Endocrinol. 57, 577–585 (2002)CrossRef

24.

V.A. Galton, E.T. Wood, E.A. StGermain, C.A. Withrow, G. Aldrich, G.M. StGermain, A.S. Clark, D.L. St Germain, Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. Endocrinology. 148, 3080–3088 (2007). doi:10.1210/en.2006-1727 CrossRefPubMed

25.

M. Bauer, A. Heinz, P.C. Whybrow, Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol. Psychiatry. 7, 140–156 (2002). doi:10.1038/sj.mp.4000963 CrossRefPubMed

26.

E.A. McAninch, S. Jo, N.Z. Preite, E. Farkas, P. Mohacsik, C. Fekete, P. Egri, B. Gereben, Y. Li, Y. Deng, M.E. Patti, C. Zevenbergen, R.P. Peeters, D.C. Mash, A.C. Bianco, Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes. J. Clin. Endocrinol. Metab. 100, 920–933 (2015). doi:10.1210/jc.2014-4092 CrossRefPubMedPubMedCentral

27.

M. Torlontano, C. Durante, I. Torrente, U. Crocetti, G. Augello, G. Ronga, T. Montesano, L. Travascio, A. Verrienti, R. Bruno, S. Santini, P. D’Arcangelo, B. Dallapiccola, S. Filetti, V. Trischitta, Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J. Clin. Endocrinol. Metab. 93, 910–913 (2008). doi:10.1210/jc.2007-1067 CrossRefPubMed

28.

M.G. Castagna, M. Dentice, S. Cantara, R. Ambrosio, F. Maino, T. Porcelli, C. Marzocchi, C. Garbi, F. Pacini, D. Salvatore, DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. J. Clin. Endocrinol. Metab. (2017). doi:10.1210/jc.2016-2587 CrossRef

29.

H.J. Wouters, H.C. van Loon, M.M. van der Klauw, M.F. Elderson, S.N. Slagter, A.M. Kobold, I.P. Kema, T.P. Links, J.V. van Vliet-Ostaptchouk, B.H. Wolffenbuttel, No effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life, and cognitive functioning in a large population-based cohort study. Thyroid. 27, 147–155 (2017). doi:10.1089/thy.2016.0199 CrossRefPubMed

30.

W.M. van der Deure, P.S. Hansen, R.P. Peeters, A.G. Uitterlinden, M. Fenger, K.O. Kyvik, L. Hegedus, T.J. Visser, The effect of genetic variation in the type 1 deiodinase gene on the interindividual variation in serum thyroid hormone levels: an investigation in healthy Danish twins. Clin. Endocrinol. 70, 954–960 (2009). doi:10.1111/j.1365-2265.2008.03420.x CrossRef

31.

J.M. Dora, W.E. Machado, J. Rheinheimer, D. Crispim, A.L. Maia, Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur. J. Endocrinol. 163, 427–434 (2010). doi:10.1530/eje-10-0419 CrossRefPubMed

32.

B.C. Appelhof, R.P. Peeters, W.M. Wiersinga, T.J. Visser, E.M. Wekking, J. Huyser, A.H. Schene, J.G. Tijssen, W.J. Hoogendijk, E. Fliers, Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3’-triiodothyronine therapy. J. Clin. Endocrinol. Metab. 90, 6296–6299 (2005). doi:10.1210/jc.2005-0451 CrossRefPubMed

33.

R. Cooper-Kazaz, W.M. van der Deure, M. Medici, T.J. Visser, A. Alkelai, B. Glaser, R.P. Peeters, B. Lerer, Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J. Affect. Disord. 116, 113–116 (2009). doi:10.1016/j.jad.2008.10.019 CrossRefPubMed

34.

E. Galecka, M. Talarowska, M. Maes, K.P. Su, P. Gorski, J. Szemraj, Polymorphisms of iodothyronine deiodinases (DIO1, DIO3) genes are not associated with recurrent depressive disorder. Pharmacol. Rep. 68, 913–917 (2016). doi:10.1016/j.pharep.2016.04.019 CrossRefPubMed

35.

V. Panicker, C. Cluett, B. Shields, A. Murray, K.S. Parnell, J.R. Perry, M.N. Weedon, A. Singleton, D. Hernandez, J. Evans, C. Durant, L. Ferrucci, D. Melzer, P. Saravanan, T.J. Visser, G. Ceresini, A.T. Hattersley, B. Vaidya, C.M. Dayan, T.M. Frayling, A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J. Clin. Endocrinol. Metab. 93, 3075–3081 (2008). doi:10.1210/jc.2008-0397 CrossRefPubMedPubMedCentral

36.

R. Peeters, C. Fekete, C. Goncalves, G. Legradi, H.M. Tu, J.W. Harney, A.C. Bianco, R.M. Lechan, P.R. Larsen, Regional physiological adaptation of the central nervous system deiodinases to iodine deficiency. Am. J. Physiol. Endocrinol. Metab. 281, E54–E61 (2001)CrossRef

37.

F.A. Verburg, J.W. Smit, I. Grelle, T.J. Visser, R.P. Peeters, C. Reiners, Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy. Clin. Endocrinol. 76, 577–581 (2012). doi:10.1111/j.1365-2265.2011.04262.x CrossRef

38.

B. He, J. Li, G. Wang, W. Ju, Y. Lu, Y. Shi, L. He, N. Zhong, Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog. Neuropsychopharmacol. Biol. Psychiatry. 33, 986–990 (2009). doi:10.1016/j.pnpbp.2009.05.003 CrossRefPubMed

Title: The relationship of 19 functional polymorphisms in iodothyronine deiodinase and psychological well-being in hypothyroid patients
Authors: Yoon Young Cho
Hye Jeong Kim
Hye Won Jang
Tae Hyuk Kim
Chang-Seok Ki
Sun Wook Kim
Jae Hoon Chung
Publication date: 01-07-2017
Publisher: Springer US
Published in: Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-017-1307-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals

The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial

Resection of tumors of the third ventricle involving the hypothalamus: effects on body mass index using a dedicated surgical approach

Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice

Does pasireotide directly modulate skeletal muscle metabolism?

Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage